Upstream Bio (UPB) Amortizatization of Intangibles (2023 - 2026)
Upstream Bio's (UPB) quarterly Amortizatization of Intangibles came in at $754000.0 in Q1 2026, down 56.54% year-on-year from $1.7 million in Q1 2025, and up 154.96% quarter-over-quarter from -$1.4 million in Q4 2025.
Upstream Bio (UPB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Upstream Bio's Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $754000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 56.54% year-over-year to $754000.0 in Q1 2026; TTM through Mar 2026 was $521000.0, a 81.17% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 9.24% from the prior year.
- Amortizatization of Intangibles climbed to $754000.0 in Q1 2026 per UPB's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q1 2025 and bottomed at -$1.4 million in Q4 2025.
- The 4-year median for Amortizatization of Intangibles is $597500.0 (2024), against an average of $415900.0.
- Across the five-year window, Amortizatization of Intangibles tumbled 375.0% in 2024 and jumped 178.49% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $248000.0 in 2023, then tumbled by 375.0% to -$682000.0 in 2024, then plunged by 101.17% to -$1.4 million in 2025, then jumped by 154.96% to $754000.0 in 2026.
- Per Business Quant, the three latest UPB Amortizatization of Intangibles figures stand at $754000.0 (Q1 2026), -$1.4 million (Q4 2025), and $154000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 3.22 Mn |
| 10 | Upstream Bio | 343.65 Mn | 343.65 Mn | -3.94 Mn | 754,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | -1.37 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | 154,000.00 |
| Sep 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 985,000.00 |
| Jun 30, 2025 | 985,000.00 |
| Mar 31, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | -682,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 623,000.00 |
| Mar 31, 2024 | 623,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Dec 31, 2023 | 248,000.00 |